NorthWest Biotherapeutics Inc (NWBO)

[AVII77]

It's really hard to tell if they earned the 2.8 months. I think the 11 crossovers in the first cohort and 22 crossovers in the overall cohort ruins the 4.9 month per protocol advantage.

I've thought carefully about this and I would agree.

Excluding from the PP survival analysis the control patients who crossed over to Optune introduces a patient selection bias and is a valid criticism of the PP results.

I would be a hypocrite to not agree.

This is the very same issue I noted with the DCVax Direct data where I said it was a meaningless observation that "stable disease at 8 weeks correlates with survival".

You might not see that it is the same issue, but it is.